Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons

Transfusion

Volumn 49, Issue 1, 2009, Pages 64-74

  Goodrich, Raymond P ^a   Murthy, Krishna K ^b   Doane, Suzann K ^b   Fitzpatrick, Christy N ^b   Morrow, La Shayla ^b   Arndt, Patricia A ^b   Reddy, Heather L ^b   Buytaert Hoefen, Kimberley A ^b   Garratty, George ^b  

^a Navigant Biotechnologies Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; HAPTEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; MEPACRINE MUSTARD; RIBOFLAVIN;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BLOOD AUTOTRANSFUSION; BLOOD SAMPLING; CELL SURVIVAL; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; MALE; NONHUMAN; ULTRAVIOLET RADIATION;

ANIMALS; BLOOD TRANSFUSION, AUTOLOGOUS; CELL SURVIVAL; DISINFECTION; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; IMMUNOGLOBULIN G; PAPIO CYNOCEPHALUS; PHOTOSENSITIZING AGENTS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 58149141482     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01940.x     Document Type: Article

References (39)

1. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007 47 : 2338 47.
2. Goodrich RP, Platz MS. The design and development of selective, photoactivated drugs for sterilization of blood products. Drugs of the Future 1997 22 : 159 71.
3. Wagner SJ, Skripchenko A. Investigation of photosensitizing dyes for pathogen reduction in red cell suspensions. Biotech Distochem 2003 78 : 171 7.
4. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med 2001 11 : 149 75.
5. Rios JA, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, Wages D, Cook D, Corash L. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006 46 : 1778 86.
6. Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005 45 : 1739 49.
7. Lazo A, Tassello J, Jayarama V, Ohagen A, Gibaja V, Kramer E, Marmorato A, Billia-Shaveet D, Purmal A, Brown F, Chapman J. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 2002 83 : 313 23.
8. Purmal A, Valeri CR, Dzik W, Pivacek L, Ragno G, Lazo A, Chapman J. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002 42 : 139 45.
9. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion 1994 34 : 521 6.
10. Wagner SJ, Storry JR, Mallory DA, Stromberg RR, Benade LE, Friedman LI. Red cell alterations associated with virucidal methylene blue phototreatment. Transfusion 1993 33 : 30 6.
11. Wagner SJ, Skripchenko A, Robinette D, Mallory DA, Cincotta L. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue. Transfusion 1998 38 : 729 37.
12. Rywkin S, Ben-Hur E, Reid ME, Oyen R, Ralph H, Horowitz B. Selective protection against lgG binding to red cells treated with phthalocyanines and red light for virus inactivation. Transfusion 1995 35 : 414 20.
13. Rywkin S, Ben-Hur E, Malik Z, Prince AM, Li YS, Kenney ME, Oleinick NL, Horowitz B. New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates. Photochem Photobiol 1994 60 : 165 70.
14. Ben-Hur E, Chan WS, Yim Z, Zuk MM, Dayal V, Roth N, Heldman E, Lazo A, Valeri C, Horowitz B. Photochemical decontamination of red blood cell concentrates with silicon phthalocyanine PC 4 and red light. Dev Biol (Basel) 2000 102 : 149 55.
15. Wagner SJ, Skripchenko A, Cincotta L, Thompson-Montgomery D, Awatefe H. Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties. Transfusion 2005 45 : 752 60.
16. Trannoy LL, Terpstra FG, de Korte D, Lagerberg JW, Verhoeven AJ, Brand A, van Engelenburg FA. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation. Vox Sang 2006 91 : 111 8.
17. Skripchenko A, Wagner SJ, Thompson-Montgomery D, Awatefe H. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion 2006 46 : 213 9.
18. Seghatchian J, de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006 35 : 189 96.
19. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
20. Goodrich RP, Edrich RA, Goodrich L, Scott C, Manica K, Hlavinka D, Hovenga N, Hansen E, Gampp D, Keil SD, Gilmour DI, Li J, Martin CB, Platz MS. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine. In : Silva E, Edwards AM, editors. Flavins: photochemistry and photobiology. Cambridge : Royal Society of Chemistry 2006. p. 83 113.
21. Reddy H, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white cell inactivation. Transfus Med Rev 2008 22 : 133 53.
22. Martin CB, Wilfong E, Ruane P, Goodrich R, Platz M. An action spectrum of the riboflavin-photosensitized inactivation of Lambda phage. Photochem Photobiol 2005 81 : 474 80.
23. Arndt PA, Garratty G. The changing spectrum of drug-induced hemolytic anemia. Semin Hematol 2005 42 : 137 44.
24. Garratty G, Arndt PA. An update on drug-induced immune hemolytic anemia. Immunohematology 2007 23 : 105 19.
25. Creech HJ, O'Connell AP. Immunochemistry of conjugates prepared from serum albumins and acridine nitrogen mustards (ICR mutagens). Cancer Res 1981 41 : 3844 51.
26. Chen RF. Fluorescence of quinacrine mustard conjugated to proteins. Arch Biochem Biophys 1976 172 : 39 50.
27. Dise CA, Burch JW, Goodman DB. Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J Biol Chem 1982 257 : 4701 4.
28. Creech HJ, O'Connell AP. Immunochemistry of conjugates prepared from serum albumins and acridine nitrogen mustards (ICR mutagens). Cancer Res 1981 41 : 3844 51.
29. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia (PA) : Churchill Livingstone 2004.
30. Garratty G. Immunogenic issues with the use of pathogen-inactivated RBCs. In : Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA, editors. Proceedings of a consensus conference: pathogen inactivation - making decisions about new technologies. Transfus Med Rev 2008 22 : 16 7.
31. Benjamin RJ. Red blood cell pathogen reduction: in search of serological agnosticism. ISBT Sci Ser 2006 1 : 222 6.
32. Conlan MG, Stassinopoulos A, Garratty G, Wages D, Corash L, Wood L, Sloan SR, Labotka RJ. Antibody formulation to S-303-treated RBCs in setting of chronic RBC transfusion (abstract). Blood 2004 104 : 112a.
33. Jusko WJ, Levy G. Plasma protein binding of riboflavin and riboflavin 5′-phosphate in man. J Pharm Sci 1969 58 : 58 62.
34. Merrill AH, Innis-Whitehouse WS, McCormick DB. Characterization of human riboflavin-binding immunoglobulins. In : Edemondson DE, McCormick DB, editors. Flavins and flavoproteins. Berlin : Walter de Gruyer & Co 1987. p. 445 8.
35. Tapia G, Silva E. Photo-induced riboflavin binding to the tryptophan residues of bovine and human serum albumin. Radiat Environ Biophys 1991 30 : 131 8.
36. Safety and performance of MIRASOL® PRT treated platelet transfusion products. Lakewood (CO) : Navigant Biotechnologies 2006. Available from: http://clinicaltrials.gov/ct/show/NCT00263809?order=1
37. Valeri CR, Pivacek LE, Cassidy GP, Ragno G. Volume of RBCs, 24- and 48-hour posttransfusion survivals, and the lifespan of (51)Cr and biotin-X-N-hydroxysuccinimide (NHS)-labeled autologous baboon RBCs: effect of the anticoagulant and blood pH on (51)Cr and biotin-X-NHS elution in vivo. Transfusion 2002 42 : 343 8.
38. Valeri CR, MacGregor H, Giorgio A, Srey R, Ragno G. Comparison of radioisotope methods and a nonradioisotope method to measure the RBC volume and RBC survival in the baboon. Transfusion 2003 43 : 1366 73.
39. Valeri CR, Lindberg JR, Contreras TJ, Pivacek LE, Austin RM, Valeri DA, Gray A, Emerson CP. Measurement of red blood cell volume, plasma volume, and total blood volume in baboons. Am J Vet Res 1981 42 : 1025 9.